Health
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a fundamental mediator in patients whose hypertension is difficult-to-control.Hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality. Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025Idorsia Ltd (SIX: IDIA) announces that its novel
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Endothelin is upregulated in hypertension and is a fundamental mediator in patients whose hypertension is difficult-to-control.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality.","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":388,"olType":false},{"type":"text","content":"Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list TRYVIO as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension. TRYVIO is the first systemic hypertension treatment to target a new pathway in over 30 years and the only new medicine to be included in the updated guidelines.","length":733,"tagName":"p"},{"type":"text","content":"Despite progress in improving patient outcomes, hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality, affecting an estimated 50% of adults in the US, with 50% of those patients not well controlled despite being on medication.","length":293,"tagName":"p"},{"type":"text","content":"TRYVIO is in...